Crispr Therapeutics shares tumble after significant earnings miss
Karen McGinnis, a director at Alphatec Holdings , Inc. (NASDAQ:ATEC), recently sold 38,320 shares of the company’s common stock. The medical technology company, currently valued at $1.77 billion, has shown strong momentum with a 76% surge in stock price over the past six months according to InvestingPro data. The transactions, executed on March 3, were conducted under a Rule 10b5-1 trading plan she adopted in December 2024 to cover tax withholding obligations from vesting restricted stock units. The shares were sold at a weighted average price of $12.26, with sale prices ranging from $12.10 to $12.56. Following these sales, McGinnis retains ownership of 57,541 shares in the company. InvestingPro analysis shows ATEC maintains a GOOD overall financial health score, with revenue growing at 26.8% year-over-year. For deeper insights into insider trading patterns and comprehensive financial analysis, including exclusive ProTips, check out the ATEC Pro Research Report, part of the 1,400+ stock coverage available on InvestingPro.
In other recent news, Alphatec Holdings reported its fourth-quarter 2024 earnings, revealing a revenue of $177 million, which exceeded analyst expectations of $170.35 million. However, the company missed its earnings per share (EPS) forecast significantly, reporting -$0.23 against the expected -$0.05. Despite this, Alphatec achieved its first quarter of positive cash flow since its transformation, generating $9 million in free cash flow. The company has set its revenue guidance for 2025 at $732 million, indicating a projected growth of 20%. Alphatec also announced a private offering of $300 million in convertible senior notes due 2030, with an option for an additional $50 million, aimed at qualified institutional buyers. This move has raised concerns about potential equity dilution among investors. TD Cowen maintained its Buy rating for Alphatec with a price target of $22.50, citing the company’s solid fourth-quarter performance and positive cash flow outlook for 2025. The analyst firm highlighted Alphatec’s market share expansion and effective cash management strategies as key factors supporting its growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.